AbbVie Inc. 8-K

What Happened
AbbVie Inc. announced on Feb. 24, 2026 that it entered into an underwriting agreement to sell $8.0 billion aggregate principal amount of senior notes across seven series, with expected net proceeds of approximately $7.95 billion after discounts and expenses. The offering is led by J.P. Morgan, BofA Securities, Morgan Stanley and Wells Fargo and is expected to close on March 4, 2026, subject to customary conditions. AbbVie filed related prospectus supplements with the SEC on Feb. 24 and Feb. 26, 2026.

Key Details

• Total securities offered: $8.0 billion gross; expected net proceeds ≈ $7.95 billion.
• Note series (principal, coupon, price to public):
  • Floating Rate Notes due 2028: $750M, price 100.000%
  • 3.775% Notes due 2028: $1,500M, price 99.966%
  • 4.125% Notes due 2031: $1,250M, price 99.972%
  • 4.400% Notes due 2033: $1,250M, price 99.861%
  • 4.750% Notes due 2036: $1,500M, price 99.911%
  • 5.550% Notes due 2056: $1,250M, price 99.736%
  • 5.650% Notes due 2066: $500M, price 99.714%
• Use of proceeds: repay amounts outstanding under AbbVie’s $4.0B 364‑day delayed draw term loan facility maturing May 2026 (about $2.0B currently outstanding) and for general corporate purposes, which may include repaying or repurchasing other debt.
• Underwriting agreement dated Feb. 24, 2026 contains customary representations, indemnities and notes potential past/ongoing relationships between AbbVie and certain underwriters/affiliates.

Why It Matters
This offering refinances near‑term obligations (including a facility maturing in May 2026) and extends a significant portion of AbbVie’s debt across maturities through 2066. For investors, the transaction reduces short‑term refinancing pressure while increasing longer‑dated fixed‑rate liabilities; proceeds may also be used for other corporate needs including debt repurchases. The size, pricing and staggered maturities are material to AbbVie’s capital structure, interest expense profile and near‑term liquidity planning.